Technical Analysis for TEVA - Teva Pharmaceutical Industries

Grade Last Price % Change Price Change
grade F 8.8 0.00% 0.00
TEVA closed up 0.92 percent on Monday, September 28, 2020, on 49 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical TEVA trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction 0.92%
Oversold Stochastic Weakness 0.92%
Down 3 Days in a Row Weakness 2.68%
Down 4 Days in a Row Weakness 2.68%
Oversold Stochastic Weakness 2.68%
Expansion Breakdown Bearish Swing Setup 1.85%
Older End-of-Day Gignals for TEVA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 3 hours ago
Down 1% about 3 hours ago
Rose Above Previous Day's High 1 day ago
Up 1% 1 day ago
Trending on StockTwits 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. It offers generic pharmaceutical products; and basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances. The company's principal branded pharmaceutical products comprise Copaxone for multiple sclerosis; Provigil and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Azilect for the treatment of Parkinson's disease; Fentora and Actiq for the treatment of pain in opioid-tolerant adult patients with cancer; Amrix for muscle spasm in acute, painful, and musculoskeletal conditions; ProAir for the treatment of bronchial spasms; Qvar for long-term control of chronic bronchial asthma; and Qnasl Nasal Aerosol for seasonal nasal and year-round nasal allergy symptoms. The company also offers Treanda for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma; Tevagrastim/Ratiograstim that stimulate the production of white blood cells; Eporatio, which stimulates the production of red blood cells; Synribo for chronic myeloid leukemia; Plan B One-Step for emergency oral contraception; ParaGard, a non hormonal intrauterine contraceptive; hormone therapies for menopause/perimenopause; Enjuvia for vasomotor symptoms associated with menopause; and therapies for infertility and urinary incontinence. In addition, it produces active pharmaceutical ingredients in the areas of respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company distributes third party products. It has collaborative agreements with Lonza Group Ltd. and OncoGenex Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Medicine Chemistry Cancer Pharmaceutical Pain Drugs Medication Pharmaceutical Products Multiple Sclerosis Parkinson's Disease Lymphoma Asthma Leukemia Active Pharmaceutical Ingredients Chronic Lymphocytic Leukemia Treatment Of Parkinson's Disease Obstructive Sleep Apnea Fentanyl Generic Pharmaceutical Products Narcolepsy Muscle Spasm Party Products Treatment Of Chronic Lymphocytic Leukemia Urinary Incontinence Chronic Myeloid Leukemia Infertility Menopause Teva Pharmaceutical Industries

Is TEVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Sep 29 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teva Pharmaceuticals Industries Limited of Class Action Lawsuit and Upcoming Deadline – TEVA
Sep 28 ROSEN, GLOBALLY RECOGNIZED COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited; Encourages Investors with Losses in Excess of $100K to Contact the Firm – TEVA
Sep 28 Teva Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva Pharmaceutical Industries Limited To Contact The Firm
Sep 28 SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Sep 27 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teva Pharmaceuticals Industries Limited of Class Action Lawsuit and Upcoming Deadline –  TEVA
Sep 25 ROSEN, LEADING INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited; Encourages Investors with Losses in Excess of $100K to Contact the Firm - TEVA
Sep 25 Is JNJ Stock A Buy As Pharma Giant Starts Final-Phase Coronavirus Vaccine Trials?
Sep 25 Why Investors Should Take a Serious, Bullish Look on Sorrento
Sep 25 FDA issues final rule for importation of drugs from abroad
Sep 24 SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
See more TEVA news...

Indicators

Indicator Value
52 Week High 13.76
52 Week Low 6.25
Average Volume 8,970,416
200-Day Moving Average 10.68
50-Day Moving Average 10.36
20-Day Moving Average 9.06
10-Day Moving Average 8.97
Average True Range 0.36
ADX 36.74
+DI 14.97
-DI 29.07
Chandelier Exit (Long, 3 ATRs ) 8.82
Chandelier Exit (Short, 3 ATRs ) 9.54
Upper Bollinger Band 9.71
Lower Bollinger Band 8.41
Percent B (%b) 0.3
BandWidth 14.38
MACD Line -0.43
MACD Signal Line -0.47
MACD Histogram 0.0475
Fundamentals Value
Market Cap 8.94 Billion
Num Shares 1.02 Billion
EPS -6.11
Price-to-Earnings (P/E) Ratio -1.44
Price-to-Sales 0.60
Price-to-Book 0.57
PEG Ratio -0.47
Dividend 1.10
Dividend Yield 12.50%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.07
Resistance 3 (R3) 9.07 8.97 9.03
Resistance 2 (R2) 8.97 8.90 8.98 9.01
Resistance 1 (R1) 8.89 8.86 8.89 8.89 8.99
Pivot Point 8.79 8.79 8.80 8.80 8.79
Support 1 (S1) 8.71 8.72 8.71 8.71 8.61
Support 2 (S2) 8.61 8.68 8.62 8.59
Support 3 (S3) 8.53 8.61 8.58
Support 4 (S4) 8.53